z-logo
Premium
Patient perspectives on treating psoriasis with classic inpatient dithranol therapy: a retrospective patient survey
Author(s) -
Painsi Clemens,
Patscheider Michael,
Inzinger Martin,
LangeAsschenfeldt Bernhard,
Quehenberger Franz,
Wolf Peter
Publication year - 2015
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.12820
Subject(s) - dithranol , medicine , psoriasis , ustekinumab , retrospective cohort study , plaque psoriasis , patient satisfaction , dermatology , physical therapy , adalimumab , surgery , disease
Summary Background Evidence of the efficacy of dithranol and patient perspectives on the treatment is scant. Patients and Methods Using a telephone interview survey, we collected retrospective data from 63 patients (41 men [65.1 %] and 22 women [34.9 %]) who had been treated with classic inpatient dithranol (CID). PsoRA ( www.psoriasisregistry.at ) was used to obtain clinical data and treatment responses, which were then correlated with the interview responses. Results Fifty‐two (82.5 %) patients achieved a PASI75 and 51 (81 %) a PASI90 response within a median of 12.5 (range: 3 to 25) days. Ten out of twelve (83 %) patients showed a satisfactory response to CID (PASI75 or greater reduction) despite the fact that they had previously failed to adequately respond to methotrexate, oral retinoids, cyclosporine, or ustekinumab. Overall, patients recalled a median recurrence‐free interval of four (95 % CI: 3–9) months after responding to CID, which was positively correlated with the patients’ recommendation of (p = 0.018) and their overall high satisfaction with the treatment (p = 0.012). Conclusions Despite the known limitations of CID, this survey indicates that dithranol remains a highly efficacious and valuable treatment option as induction therapy in psoriasis. CID can be effective in patients who have failed to respond to systemic therapy, including traditional agents and biologics.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here